Reta is an investigational molecule suitable for once-weekly injection with the potential to treat obesity and T2D.
Reta is primarily indicated for the treatment of obesity, a condition that has reached epidemic proportions globally and is associated with numerous comorbidities, including type 2 diabetes, cardiovascular diseases, and certain cancers. Traditional weight loss medications have struggled with efficacy and safety issues, often resulting in modest weight loss and significant side effects. Retatrutide, however, has demonstrated the potential to achieve substantial weight loss with a favorable safety profile. Early-phase clinical trials have shown promising results, with patients experiencing significant reductions in body weight and improvements in metabolic health markers.
